

⁶
~~18~~. The method of claim ³~~9~~, wherein said cell is capable of undergoing necrosis in the presence of zVAD-fmk and DMSO.

⁷
~~19~~. The method of claim ³~~9~~, wherein said cell is mammalian.

¹¹
~~23~~. The method of claim ³~~9~~, wherein said compound is in a pharmaceutically acceptable carrier.

¹⁴
~~32~~. The method of claim ¹²~~24~~, wherein said condition is a neurodegenerative disease.

¹⁶
~~34~~. The method of claim ¹²~~24~~, wherein said condition is selected from the group consisting of ischemic brain injury, ischemic heart injury, and head trauma.

¹⁷
~~35~~. The method of claim ¹²~~24~~, wherein said subject is a mammal.

Support for the Amendments

The claims have been amended to reflect the invention of Group I elected herewith. No new matter is introduced by any of these amendments. A "marked up" version of the amended claims, showing the changes made, is attached.

If there are any charges, or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date:

May 10, 2001

Kristina Bieker-Brady
Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

RECEIVED

MAY 16 2001

TECH CENTER 1600/2900

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

00742.056003 Reply to Restriction Requirement.wpd